Phase 3 Trial Will Assess Darzalex-containing Combo Therapy in Multiple Myeloma Patients
The anti-CD38 agent Darzalex (daratumumab) will be investigated in…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA Places Hold on BioInvent’s Phase 2 Trial for Multiple Myeloma Therapy
The U.S. Food and Drug Administration (FDA) has verbally…
Karyopharm to Present Updated Clinical Data of Selinexor in Multiple Myeloma Patients
Karyopharm Therapeutics is set to present novel clinical…
MorphoSys to Present Proprietary Hemato-Oncological Antibody Programs at ASH 2016
MorphoSys, the creator of HuCAL (Human Combinatorial Antibody…
Genentech to Present Data From Multiple Clinical Trials on Myeloma and Other Blood Cancers
Genentech will present results on several approved or…
Clinical Trial Will Assess Immunotherapy Combo in Multiple Myeloma Patients in 2017
Adaptimmune Therapeutics and Merck have agreed to begin a…
